NATCO Pharma Announces Investment of USD 8 Million in eGenesis
The eGenesis Genome Engineering and Production (EGEN) Platform is the only technology to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.
EGenesis | 04/09/2024 | By Aishwarya | 209
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy